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SUMMARY. Hepatitis C virus (HCV) antiviral treatment for
people who inject drugs (PWID) could prevent onwards
transmission and reduce chronic prevalence. We assessed
current PWID treatment rates in seven UK settings and
projected the potential impact of current and scaled-up
treatment on HCV chronic prevalence. Data on number
of PWID treated and sustained viral response rates (SVR)
were collected from seven UK settings: Bristol (37–48%
HCV chronic prevalence among PWID), East London
(37–48%), Manchester (48–56%), Nottingham (37–44%),
Plymouth (30–37%), Dundee (20–27%) and North Wales
(27–33%). A model of HCV transmission among PWID
projected the 10-year impact of (i) current treatment
rates and SVR (ii) scale-up with interferon-free direct
acting antivirals (IFN-free DAAs) with 90% SVR. Treat-
ment rates varied from <5 to over 25 per 1000 PWID.
Pooled intention-to-treat SVR for PWID were 45% geno-
types 1/4 [95%CI 33–57%] and 61% genotypes 2/3
[95%CI 47–76%]. Projections of chronic HCV prevalence
among PWID after 10 years of current levels of treat-
ment overlapped substantially with current HCV preva-
lence estimates. Scaling-up treatment to 26/1000 PWID
annually (achieved already in two sites) with IFN-free
DAAs could achieve an observable absolute reduction in
HCV chronic prevalence of at least 15% among PWID
in all sites and greater than a halving in chronic HCV
in Plymouth, Dundee and North Wales within a decade.
Current treatment rates among PWID are unlikely to
achieve observable reductions in HCV chronic prevalence
over the next 10 years. Achievable scale-up, however,
could lead to substantial reductions in HCV chronic
prevalence.
Keywords: antiviral treatment, direct acting antivirals,
hepatitis C virus, injecting drug users, people who inject
drugs, prevention, sustained viral response.
INTRODUCTION
Chronic hepatitis C virus (HCV) infection is a leading cause
of liver disease, death and disability [1,2]. In the United
States, more people die each year from HCV than HIV [3].
Preventing HCV transmission is critical for averting future
liver disease [4]. In many developed countries and develop-
ing countries with injecting drug use, this principally
involves controlling HCV infection among people who
inject drugs (PWID) [5,6]. For example, in the United King-
dom, nearly 200 000 people (0.5% of adults aged 15–60)
are infected with HCV, of which over 85% acquired HCV
through injecting drug use [7].
The combination of opiate substitution treatment (OST)
and high-coverage needle and syringe programmes (NSP)
can reduce HCV transmission among PWID [8,9]. How-
ever, it is unlikely that OST and high-coverage NSP can be
sustained sufficiently to achieve substantial reductions in
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rals; HCV, hepatitis C virus; ITT, intention to treat; NSP, needle
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HCV prevalence among PWID [10], and no community
has achieved a marked reduction with this approach.
Model projections have suggested that HCV treatment
among PWID could be effective as primary prevention (i.e.
‘treatment as prevention’) [11–16] and that treating PWID
may be more cost-effective than treating ex/former PWID
with no ongoing transmission/infection risk in many set-
tings [12]. Indeed, mathematical models have suggested
that scaling up of HCV treatment is required to achieve a
reduction in HCV prevalence of over 40% among PWID in
the next decade [17].
Epidemiological data suggest that PWID can be treated
and achieve similar sustained viral response (SVR) as other
groups, especially if incorporated with OST [18,19]. None-
theless, overall HCV treatment rates remain low, and evi-
dence on the number of PWID treated is sparse, as data on
injecting status are not always routinely collected during
HCV treatment [20]. The imminent availability of inter-
feron-free direct acting antiviral (IFN-free DAA) therapies
will dramatically change the HCV treatment landscape – if
once-daily all-oral interferon-free regimes with high SVR
rates (~90%), short duration (12–24 weeks), low toxicity,
high barrier to resistance and reduced monitoring can be
achieved and translated to real world settings [21–28].
In this study, we determined current treatment rates
and outcomes among PWID in selected sites in the United
Kingdom and projected the likely impact of these treatment
rates on chronic HCV prevalence among PWID over the
next decade, as well as considered the impact of HCV treat-
ment scale-up and use of new IFN-free DAAs.
METHODS
Service evaluation
The United Kingdom, like many other countries, lacks rou-
tine data on the number of people who inject drugs
(PWID) treated for HCV from public health or clinical
reporting systems [29]. Therefore, we undertook an anony-
mous service evaluation of seven UK sites: five in England
[Bristol, East London (Newham, Hackney and Tower Ham-
lets), Plymouth, Nottingham, and Manchester], one in
Scotland (Dundee and Tayside, including Angus, Perth and
Kinross) and one in Wales comprising North West and
North East Wales (Betsi Cadwaladr). Dependent heroin use
is a chronic relapsing condition – with no absolute defini-
tion of long-term injecting cessation [30,31]. We classified
recent PWID as people who at the time of their HCV treat-
ment were currently injecting, reported injecting in the last
3 years and/or were on OST. One additional potential site
was excluded because consistent data on number of PWID
treated could not be collected. Lead physicians and nurses
(in hepatology or infectious diseases) in each site provided
information on the number of PWID treated during 2009–
2011 and HCV treatment SVR rates by genotype with
pegylated interferon and ribavirin (pegIFN/RBV). SVR data
for recent PWID were pooled to generate estimates by
genotype for use in model projections (Table 1). There was
moderate to high heterogeneity between sites; therefore,
we used a random effects model including the site as a
random effect for the estimates of SVR – with each site
contributing approximately equally to the weighted aver-
age. We estimated two sets of SVR – either excluding cases
with missing follow-up information (a per protocol analysis
that assumes information on SVR was missing completely
at random, designated ‘per protocol SVR’ and a best case
scenario) or classifying people with missing SVR as treat-
ment failures (designated as ‘Intention To Treat’ ITT SVR
and a worst case scenario).
Additionally, we collated baseline data on HCV seropre-
valence among PWID and number of PWID (appendix
Tables S1,S2). Estimates for the number of PWID were
used to calculate the annual HCV treatment rates per
1000 PWID for model projections (Table 1, details in
appendix), where the denominator is the total number of
PWID (not the estimated number with chronic HCV).
Mathematical model
We used a previously published dynamic, deterministic,
compartmental model of HCV transmission and treatment
among PWID [11]. The model included compartments for
uninfected PWID (X(t)), PWID chronically infected with
HCV (C(t)), PWID on antiviral treatment (T(t)) and PWID
who failed antiviral treatment (F(t)). We tracked changes
in the populations over time, t. As the model is dynamic,
the risk of infection or reinfection for a PWID is propor-
tional to HCV chronic prevalence, which changes over
time. We did not assume any risk difference after treat-
ment; reinfection risk is equal to primary infection risk. For
details model and equations, see appendix.
Scenarios examined
We evaluated four treatment scenarios with varying SVR
rates:
• SVR with pegIFN/RBV based on the intention-to treat-
analysis (‘ITT SVR’) for 10 years with existing PWID
treatment rates
• SVR with pegIFN/RBV ignoring patients missing SVR
data post-treatment completion (‘per protocol SVR’) for
10 years with existing PWID treatment rates
• ITT SVR until 2015, with IFN-free DAAs for genotype 1
patients only (90% SVR [21–28]) from early 2016
onwards and a scale up of treatment to 26 per 1000
PWID (the upper estimate of what is currently achieved
in Manchester and Nottingham) (‘conservative DAA
scenario’)
• Per protocol SVR until 2015, with IFN-free DAAs for all
genotypes (90% SVR [21–28]) from early 2016 onwards
and a scale up of treatment to 26 per 1000 PWID (the
© 2014 The Authors Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.
400 N. K. Martin et al.
upper estimate of what is currently achieved in Man-
chester and Nottingham) (‘optimistic DAA scenario’)
Clinical guidance in the United Kingdom recommended
against treatment of PWID prior to 2002 [32], and PWID
treatment rates prior to this study are unknown. Therefore,
we assumed that current treatment rates have been in
place for 5 years prior to 2014 (2009 onwards).
Multivariate uncertainty analyses
To consider the effect of uncertainty in the underlying
parameters, we performed a multivariate probabilistic uncer-
tainty analysis where 1000 parameter sets were randomly
sampled from setting specific parameter distributions in
Table 1. For each of the 1000 parameter sets, the model was
calibrated to the sampled HCV chronic prevalence in 2013
by varying the infection rate, p. The model was assumed to
be in steady state prior to 2009, such that both the number
of PWID and also the chronic HCV prevalence among PWID
were stable. From 2009 to 2014, the model also took into
account HCV treatment rates achieved by the sites and then
was used to project the prevalence reductions in each setting
for a further 10 years with current treatment rates or
scaled-up treatment rates. For all projections, 95% intervals
were generated from the multivariate uncertainty sampling.
A linear regression analysis of covariance (ANCOVA) was
performed on the 10-year relative prevalence reduction, and
the proportion of the sum of squares contributed by each
parameter was calculated to estimate the importance of
individual parameters to the overall uncertainty [33]. All
equations were solved using MATLAB, using the ordinary
differential equation solver ODE45.
Parameters
A list of the parameters used in the modelling simulations
can be found in appendix Tables S1,S2.
RESULTS
Survey of treatment centres
We received data on a total of 1337 people treated for
HCV in the participating sites; of which 927 were resident
in the sites and 538 (58%) were classified as PWID (i.e.
current or recent injectors or on OST), 54 (6%) recent
injecting status was unknown, and 335 (36%) were
exposed through other routes or last injected more than
3 years from date of HCV treatment and were not on OST.
Annual HCV treatment rates varied from an estimated
rate per 1000 PWID of <5 to over 25 (Table 1). Individual
and pooled estimates of SVR for PWID are presented in
Fig. 1, with pooled results listed in Table 1. The pooled ITT
Table 1 Service evaluation results
Parameter Value/Range Notes
Sustained viral response rate
Peg-IFN/RBV G1/4 ITT* 45% [95%CI 33–57%] Sampled from a uniform distribution in model projections
Peg-IFN/RBV G2/3 ITT* 61% [95%CI 46–76%]
Peg-IFN/RBV G1/4 per protocol** 59% [95%CI 46–71%]
Peg-IFN/RBV G2/3 per protocol** 82% [95%CI 69–94%]
Number PWID treated per year
Bristol 18
East London 25
Manchester 63
Nottingham 32
Plymouth 17
Tayside/Dundee 34
North Wales 18
Treatment rate per 1000 PWID in 2013
Bristol 4.1–5.6 Calculated from estimated number PWID (see appendix);
uncertainty due to uncertainty in number of PWID.
Sampled from a uniform distribution in model projections
East London 4.2–10.4
Manchester 15.8–27.4
Nottingham 12.8–24.6
Plymouth 8.5–15.5
Tayside/Dundee 11.3–17.0
North Wales 5.3–10.6
PWID = people who use drugs; G1/4 = genotypes 1 and 4; G2/3 = genotypes 2 and 3; ITT: intention to treat. *Analysis
classifying people with missing SVR as treatment failures. **Analysis excluding cases with missing follow-up information/
missing classified as completely at random.
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SVR (assuming those lost to follow-up were treatment fail-
ures) was 61% (95%CI 46–76) for genotype 2/3 and 45%
(95%CI 33–57) for genotype 1/4. The pooled per protocol
SVR (ignoring missing follow-up data) was 82% (95%CI
69–94) for genotype 2/3 and 59% (95%CI 46–71) for
genotype 1/4. There was weak evidence that SVR varied
by site (Fig. 1). We stratified sites by their treatments rates,
defining settings as low treatment (<11 per 1000 PWID
treatments: Bristol, East London, North Wales) and high
treatment (≥11 per 1000 PWID treatments: Manchester,
Nottingham, Plymouth, Dundee). High treatment sites
tended to have lower SVR than low treatment sites: for
genotype 2/3 ITT SVR, the odds ratio was 0.35 (95%CI
0.15–0.82) comparing sites with high versus low treat-
ment rates adjusted for age, and for genotype 1/4 ITT, the
odds ratio was 0.82 (95%CI 0.45–1.49) comparing high
vs. low treatment sites after adjustment for age. None of
the sites had systematic follow-up of successfully treated
patients to assess reinfection.
Model projections
Figure 2a shows the HCV chronic prevalence among PWID
at 10 years using the ITT SVR or per protocol SVRs for
peg-IFN+RBV assuming a continuation of current treat-
ment rates. With current treatment rates and the ITT SVR,
modest impact will be achieved at 10 years, with no set-
tings achieving absolute chronic prevalence reductions of
10%. At 10 years, the 95% interval of projected HCV
chronic prevalence among PWID would largely overlap
with the current estimates (Fig. 2a) including from 48–
56% vs 43–53% in Manchester, 37–48% vs 36–47% in
Bristol, 37–48% vs 35–46% in East London, 48–56% vs
30–40% in Nottingham, 30–37% vs 25–34% in Plymouth,
20–27% vs 23-31% in North Wales, 20–27% vs 13–22%
in Dundee. Using the higher per protocol SVR for peg-IFN/
RBV increases the potential impact (by approximately 30–
40%), but the uncertainty estimates still overlap. Two
settings potentially achieve absolute chronic prevalence
NOTE: Weights are from random effects analysis
Overall  (I-squared = 71.7%, P = 0.002)
Nottingham
London
Manchester
Site
Plymouth
Wales
Dundee
Bristol
0.59 (0.46, 0.71)
0.57 (0.41, 0.72)
0.50 (0.32, 0.68)
0.47 (0.36, 0.58)
ES (95% CI)
0.35 (0.14, 0.62)
0.75 (0.48, 0.93)
0.84 (0.64, 0.95)
0.63 (0.35, 0.85)
100.00
15.74
14.54
18.05
%
Weight
11.96
12.47
15.69
11.55
NOTE: Weights are from random effects analysis
Overall  (I-squared = 76.2%, P = 0.000)
Plymouth
Manchester
Bristol
Wales
Site
Nottingham
Dundee
London
0.45 (0.33, 0.57)
0.29 (0.11, 0.52)
0.29 (0.22, 0.37)
0.59 (0.33, 0.82)
0.40 (0.23, 0.59)
ES (95% CI)
0.52 (0.37, 0.67)
0.70 (0.51, 0.85)
0.43 (0.27, 0.61)
100.00
12.79
18.37
11.15
13.73
Weight
15.26
14.21
%
14.50
0.25 0.5 0.75 1 0.25 0.5 0.75 1
0.25 0.5 0.75 1 0.25 0.5 0.75 1
NOTE: Weights are from random effects analysis
Overall  (I-squared = 86.4%, P = 0.000)
Nottingham
Manchester
London
Plymouth
Wales
Dundee
Site
Bristol
0.61 (0.46, 0.76)
0.49 (0.32, 0.66)
0.40 (0.33, 0.47)
0.68 (0.51, 0.82)
0.48 (0.29, 0.68)
0.67 (0.38, 0.88)
0.68 (0.51, 0.82)
ES (95% CI)
0.88 (0.68, 0.97)
100.00
14.22
16.70
14.60
13.35
11.74
%
14.60
Weight
14.81
NOTE: Weights are from random effects analysis
Overall  (I-squared = 85.6%, P = 0.000)
Manchester
Bristol
Site
London
Nottingham
Plymouth
Dundee
Wales
0.82 (0.69, 0.94)
0.72 (0.63, 0.80)
0.91 (0.72, 0.99)
ES (95% CI)
0.87 (0.69, 0.96)
0.55 (0.36, 0.72)
0.72 (0.47, 0.90)
1.00 (0.87, 1.00)
0.91 (0.59, 1.00)
100.00
16.50
14.82
Weight
14.82
%
13.16
11.57
17.04
12.09
(a) (b)
(c) (d)
Fig. 1 Pooled random effects model estimates of SVR (sustained viral response) by genotype and classification of missing
data. (a) Genotype 1&4 ITT (missing follow-up classified as nonresponder/treatment failure) (b) Genotype 2&3 ITT (missing
follow-up classified as nonresponder/treatment failure) (c) Genotype 1&4 per protocol (missing follow-up excluded/classified
as completely at random) (d) Genotype 2&3 per protocol (missing follow-up excluded/classified as completely at random).
ITT = intention to treat.
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reductions of 10%: Nottingham (4–11% absolute chronic
prevalence reduction) and Dundee (6–11%).
Conversely, if current treatment rates are scaled up to
26 per 1000 PWID annually (the upper range of what is
estimated to currently occur in Manchester and Notting-
ham) and IFN-free DAAs become available in 2016, then
the model predicts substantial prevention impact (Fig. 2b).
For instance, if IFN-free DAAs only become available for
genotype 1 patients (with genotype 2/3 remaining on peg-
IFN/RBV with the lower ITT SVR), then, the model pre-
dicts all settings could achieve a 10% absolute reduction in
chronic prevalence within 10 years. At 10 years, HCV
chronic prevalence among PWID was projected to be 37–
50% (95% interval) in Manchester, 22–35% in Bristol, 22–
36% in East London, 23–34% in Nottingham, 14–24% in
Plymouth, 9–18% in North Wales and 4–12% in Dundee.
Finally, if treatment rates are scaled up to 26 per 1000
PWID annually and IFN-free DAAs are available for all
genotypes in early 2016 (Fig. 2b), then, all settings could
achieve a 15% absolute reduction in chronic prevalence
within 10 years (95% interval predicting 14–20% absolute
reduction in Bristol, 13–20% in East London, 7–16% in
Manchester, 12–19% in Nottingham, 16–21% in Plym-
outh, 18–22% in Dundee and 18–22% in North Wales).
Greater relative impact is seen in lower prevalence areas,
with relative prevalence reductions of 42–63% (95% inter-
val) in Plymouth, 70–86% in Dundee and 53–74% in
North Wales (Fig. 3).
ANCOVA analysis
The ANCOVA analysis (appendix Figure S1) indicates that
the majority of variation in the impact projections is due
to uncertainty in baseline treatment rate (contributing
>35% of uncertainty in East London, Nottingham, Plym-
outh, Dundee and North Wales), injecting duration (con-
tributing >25% uncertainty in Bristol, Manchester and
Nottingham) and baseline chronic prevalence (contributing
>20% uncertainty in Bristol, East London and Dundee).
Less impact is achieved if the baseline chronic prevalence
is towards the higher end of the estimates, if treatment
rates are towards the lower end of the estimates and if
injecting duration is at the shorter range of estimates.
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Light gray: 2024, no scale-up, per protocol SVR with IFN/RBV 
Dark gray: 2024, scale-up to 26/1000 annually with IFN-free DAAs (G1 only) in 2016 
Black: 2024, scale-up to 26/1000 annually with IFN-free DAAs (all genotypes) in 2016 
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Fig. 2 Model projections for HCV chronic
prevalence among PWID in 2014 (blue)
and in 2024 (white/gray/black) with
various treatment scenarios. (a) Projections
are shown for no treatment scale-up and
using Peg-IFN/RBV ITT SVR rates from
2005 (white), no treatment scale-up and
using Peg-IFN/RBV per protocol SVR rates
from 2005 (light gray). (b) Projections are
shown for no treatment scale-up and using
Peg-IFN+RBV ITT SVR rates from 2005
(white), no treatment scale-up and using
Peg-IFN+RBV per protocol SVR rates from
2005 (light gray), ‘conservative DAA
scale-up scenario’ with ITT SVR until
2015, treatment scale-up to 26/1000
PWID and IFN-free DAAs for genotype 1
patients only in 2016 (dark gray),
‘optimistic DAA scale-up scenario’ with per
protocol SVR until 2015, treatment scale-
up to 26/1000 PWID and IFN-free DAAs
for all genotypes in 2016 (black). Boxes
show the interquartile range, with
whiskers indicating the 95% intervals.
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DISCUSSION
We determined the current levels of HCV treatment for
people who inject drugs (PWID) and SVR rates for Peg-
IFN/RBV in a range of sites in the United Kingdom and
showed that these were unlikely to achieve observable
reductions in HCV prevalence over the next 10 years.
However, with the introduction of IFN-free DAAs in 2016
and scale up of HCV treatment to rates achieved at two
sites (~26 per 1000 PWID or from 29 to 156 treatments
annually in the sites), then all sites could achieve at least
a 15% absolute reduction in HCV prevalence with relative
reductions ranging from 12% to 86% after 10 years.
Greater impact is achieved in sites with lower HCV preva-
lence, although we also show that uncertainty on key
parts of the evidence (such as PWID prevalence and base-
line treatment rates) leads to substantial variation in the
projected impact.
We collected data on over 500 PWID – more than previ-
ous systematic reviews and other observational cohorts
[18]. Our model projections, however, are subject to con-
siderable uncertainty because of uncertainty around some
key influential parameters.
First, the true duration of injecting drug use is difficult
to estimate and remains uncertain [34]. However, we
believe that duration is likely to be prolonged (with aver-
age duration >8–10 years) [30], therefore increasing the
opportunity for HCV treatment to avert HCV infections
[17]. Second, despite the largest public health surveillance
programme in Europe, local estimates of HCV prevalence
are uncertain and contribute to over 1/3 of the variability
in model projections [35].
Third, we may have misclassified some PWID (as current
injecting status was unknown for 6% of the sample, a pro-
portion of people in OST may have a very low risk of
relapse and a proportion of those that had last injected
greater than 3 years also may relapse). However, this vari-
ability is dwarfed by the uncertainty in the denominator –
the prevalence of PWID. We are very concerned over the
credibility and reliability of estimates of PWID prevalence
in general– which is a key input to the model projections –
and an important source of caution for the projections
[36]. Until more reliable and consistent estimates are gen-
erated, there will inevitably be uncertainty over the impact
of treatment scale-up on HCV incidence and prevalence.
Fourth, we revealed uncertainty in the SVR with Peg-
IFN/RBV – due in part to heterogeneity in local sites but
primarily due to missing follow-up information. Addition-
ally, PWID who have been previously treated may be sub-
ject to selection bias, and outcomes may not be
representative if treatment were to be scaled up to the
broader PWID population. However, it was strength that
the reported SVR was consistent with published estimates
from trials and other observational studies [18,19].
Although SVR of new DAAs in ‘real world’ remains
unmeasured, we expect it to be greater than current
White: No scale-up, ITT SVR with IFN/RBV 
Light gray: No scale-up, per protocol SVR with IFN/RBV 
Dark gray: Scale-up to 26/1000 annually with IFN-free DAAs (G1 only) in 2016 
Black: Scale-up to 26/1000 annually with IFN-free DAAs (all genotypes) in 2016 
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Fig. 3 Relative HCV chronic prevalence reductions among PWID at 10 years assuming various treatment scenarios.
Projections are shown for no treatment scale-up and using Peg-IFN/RBV ITT SVR rates from 2005 (white), no treatment
scale-up and using Peg-IFN/RBV per protocol SVR rates from 2005 (light gray), ‘conservative DAA scale-up scenario’ with
ITT SVR until 2015, treatment scale-up to 26/1000 PWID and IFN-free DAAs for genotype 1 patients only in 2016 (dark
gray), ‘optimistic DAA scale-up scenario’ with per protocol SVR until 2015, treatment scale-up to 26/1000 PWID and
IFN-free DAAs for all genotypes in 2016 (black). Boxes show the interquartile range, with whiskers indicating the 95%
intervals.
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treatments. Additionally, although we explore a scenario
where IFN-free DAAs are only approved for genotype 1
patients, it is unclear whether they will immediately be
funded and made available for all disease stages (such as
mild fibrosis). Nevertheless, given the rapid developments
in HCV therapy, an all-oral, pan-genotype, high-efficacy
treatment for all stages is likely in the very near future
[21–28].
Finally, we assumed no change in risk behaviour follow-
ing treatment such that reinfection incidence equals pri-
mary incidence, despite evidence that reinfection rates
among PWID are low [19]. If risk behaviour is reduced fol-
lowing treatment, then, our assumption provides conserva-
tive projections of impact. However, we again note that it
is unclear whether sustained reductions in risk would be
seen if treatment were scaled up to the broader PWID
population.
Our study builds on previous work that has shown that
scaling-up HCV treatment among injectors can lead to sub-
stantial reductions in HCV chronic prevalence among
PWID and that HCV treatment is critical to primary pre-
vention of HCV [11–16]. A recent modelling study esti-
mated that scaling-up HCV DAA treatment in the general
population could dramatically reduce the number of
chronic infections in England [37], but did not include
dynamic transmission of HCV among PWID, the risk of
reinfection after treatment or the population prevention
benefit of treatment of PWID. Therefore, in settings with
ongoing HCV transmission, dynamic epidemic transmission
models as used in this manuscript are required to generate
robust estimates of the impact of treatment on the burden
of chronic infection.
There are a growing number of studies that have shown
that HCV treatment can be delivered to PWID with little
loss in SVR compared to non or ex-PWID [18, 19] and
also that treatment can be expanded among PWID, espe-
cially if linked to OST [38–42]. Our model projections
(based on real data) show that relatively high treatment
rates can be achieved (at >20 per 1000 PWID) and could
be sufficient to demonstrate ‘treatment as prevention’ in
many settings. However, we show also a fourfold variation
in HCV treatment rates of PWID across our sites in the
United Kingdom- with the lowest rates at approximately 5
per 1000 PWID equivalent to rates in Vancouver and Mel-
bourne [13]. Such variation represents the opportunities,
but also the difficulties, for scaling-up HCV treatment.
Some sites prioritized HCV treatment scale-up earlier than
others and may have found it easier to establish effective
services in the community, while others have encountered
difficulties in scaling-up traditional HCV treatments among
PWID – many of whom continue to experience chaotic
lives and may not be in OST long enough to sustain HCV
case finding and treatment [43–45].
Information on HCV treatment rates of PWID generally is
lacking. One of the key challenges to the study was collect-
ing information on PWID status, which was not always
recorded on routine clinic databases and in several
instances had to be collected from clinical notes [46]. How-
ever, it is important that routine clinical and surveillance
data on HCV record information on OST and PWID status –
so that policymakers and clinicians can monitor HCV treat-
ment rates in order both to inform treatment target setting
and to assess whether health inequalities are being reduced.
A key question is whether sufficient HCV treatment
scale-up (to observe a reduction in HCV prevalence) can
only be achieved through the introduction of new inter-
feron-free DAAs. Despite promising treatment rates in some
sites, we believe interferon-based therapy is unlikely to be
a suitable agent to provide significant enhancement of
treatment rates as it is unlikely to be acceptable to all
patients or lend itself to extensive development of commu-
nity-based treatment services. Introducing and scaling up
HCV treatment with new IFN-free DAAs, however, as a
public health ‘treatment as prevention’ intervention, are
unlikely to be affordable at current protease inhibitor (PI)
or DAA list prices, although full economic models compar-
ing different treatment strategies have not yet been
published. We have shown that optimizing OST and high-
coverage NSP can reduce the number of HCV treatments
required to reduce HCV prevalence [17]. We show here
also that a similar intervention impact can be achieved by
conserving new DAAs for genotype 1 only. We highlight
the uncertainties surrounding two important parameters
(PWID prevalence and local estimates of HCV prevalence
in PWID) that need to be resolved. Finally, it is urgent that
our model projections of the effectiveness and impact of
HCV treatment as prevention are tested empirically.
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